

Antifungal and Antiplasmodial Activity of Isolated Compounds from *Handroanthus serratifolius* (Vahl) S. Grose Sawdusts

Loretta Ennes Sabóia de Melo¹, Katia Santana Cruz², Pedro Igor Lima Soares², Claudete Catanhede do Nascimento³, João Vicente Braga de Souza², Brenna Marceliane de Melo Marcelino⁴, Valter Ferreira de Andrade-Neto⁴, Antonio Gilberto Ferreira⁵, Maria da Paz Lima^{5*}

¹Laboratório de Química de Produtos Naturais, Instituto Nacional de Pesquisas da Amazônia, Manaus-AM, Brazil

²Laboratório de Micologia Médica, Instituto Nacional de Pesquisas da Amazônia, Manaus-AM, Brazil

³Laboratório de Tecnologia da Madeira, Instituto Nacional de Pesquisas da Amazônia, Manaus-AM, Brazil

⁴Laboratório de Biologia da Malária e Toxoplasmose, Universidade Federal do Rio Grande do Norte, Natal-RN, Brazil

⁵Laboratório de Ressonância Magnética Nuclear, Universidade Federal de São Carlos, São Carlos-SP, Brazil

*Email, corresponding author: mdapaz@inpa.gov.br

Abstract — *Handroanthus serratifolius* (Vahl) S. Grose [*Tabebuia serratifolia* (Vahl) G. Nicholson] popularly known in Brazil “ipê-amarelo” is a woody species with potential of sustainable use belonging to a genus known for being as a promising naphthoquinones source which has aroused interest in search for new biological activities. In this paper, the methanolic extract fractionation from *H. serratifolius* sawdust using different chromatographic techniques yielded naphthoquinones dehydro- α -lapachone, dehydro-iso- α -lapachone and α -lapachone, along with lignans paulownin and cyclooolivil. The three naphthoquinones presented antiplasmodial activity against *Plasmodium falciparum* where the dehydro-iso- α -lapachone was more active (IC₅₀ of 7.53 μ g/mL). This same compound also exhibited significant antifungal activity against *Cryptococcus neoformans*.

Keywords — *Bignoniaceae*, *Cryptococcus neoformans*, lignans, naphthoquinones, *Plasmodium falciparum*.

I. INTRODUCTION

Handroanthus serratifolius (Vahl) S. Grose [*Tabebuia serratifolia* (Vahl) G. Nicholson] (Bignoniaceae) is a woody species with potential of sustainable use, and with a large occurrence in South America¹. The trunk medium diameter ranging from 20-90 cm in this species foment furniture confection beyond its medicinal importance, especially the heartwood is used for pharmacological substrate. Popularly known in Brazil as “ipê”, “ipê-amarelo” and “pau-d’arco”, it is commonly used in landscaping and urban arborisation due to its attractive yellow flowers². Phytochemical studies with *H. serratifolius* (ipê-amarelo) are scarce, there are reports of two naphthoquinones derivative of lapachol from stem bark³. The naphthoquinones of Bignoniaceae have been much investigated in the last decades, especially lapachol and analogs α -lapachone and β -lapachone, which are isolated from the heartwood and exhibit a diversity of biological activities^{4,5}. The interest in three natural naphthoquinones as well as their semi-synthetic

derivatives has intensified the search for new antifungal of medical interest⁶⁻⁸ and antimalarial agents⁹⁻¹¹.

Malaria remains an important infectious disease, which is most prevalent in the tropical and poor regions of African countries. In 2017, according to the latest estimates from WHO, there were 219 million new cases, with 435,000 deaths, especially in children under five years of age¹². The appearance of *Plasmodium falciparum* resistance to many antimalarial medicines is a concern in the fight against malaria; all over the world including in Brazil^{13,14}. In this context, it is important the discovery of new drugs with new targets. Thus, in this study, we investigated antifungal and antiplasmodial potential of naphthoquinones and lignans isolated from the heartwood residues of *H. serratifolius*. Spectroscopic characterization of the compounds is also presented.

II. MATERIAL AND METHODS

General experimental procedures

NMR spectra were measured in a Bruker DRX 400

apparatus; chemical shifts (δ) were expressed in ppm, and coupling constants (J) in Hertz; TMS was used as internal standard. Deuterated solvents chloroform and methanol were purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-HRMS measurements were obtained using a MicroTOF-QII (Bruker Daltonics) mass spectrometry connected to a Prominence UFLC (Shimadzu) LC. Melting points were determined on a Fisatom 430D apparatus. Fractioning by medium pressure liquid chromatography (CLMP) was performed on CLMP–Sepacore[®] Buchi equipped with control unit (C-620), fractions collector (C-660), binary pump (C-605) and UV (C-640). Column chromatography (CC) was performed with silica gel 60 (Merck, 70-230 and 230-400 mesh), cellulose (Merck), Sephadex LH-20 (Sigma-Aldrich) and Amberlite XAD-2 (Supelco). Analytical TLC was performed with silica gel 60 F₂₅₄ (0.25 mm) pre-coated alumina sheets (Merck) visualized using UV light (254 and 365 nm), vanillin-sulphuric acid and NP/PEG reagent spray.

Obtaining of wood residues and extraction

Samples of wood residues were obtained from the Experimental Station of Tropical Forestry located at km 50 of BR-174, the basis of forest management of the Instituto Nacional de Pesquisas da Amazônia (INPA). These residues were classified and identified through macroscopic comparisons with standard samples of *H. serratifolius* available in the Xylotheque of INPA. Larger residues were previously evaluated about their technological properties of wood and use for experiments in the production of artifacts in the Laboratory of Engineering of Wood Artifacts. The resulting minor residues (sawdusts) from these procedures were available for phytochemical studies. Thus, sample of sawdusts from *H. serratifolius* heartwood (295.56 g) was extracted with n-hexane and then methanol providing 0.84 of hexane extract and 19.14 g of methanolic extract.

Chromatographic fractionation of methanolic extract

The methanolic extract (16 g) was fractionated over silica gel column (70-230 mesh) eluted with hexane, hex:CH₂Cl₂ (1:1), CH₂Cl₂, CH₂Cl₂:MeOH (10-50%) to yield twenty-one fractions. The grouped fractions 7-11 (TSM-7, 1.86 g) and 14-15 (TSM-14, 6.52 g) were subjected to further chromatographic fractionation. TSM-7 fraction was subjected to a microcrystalline cellulose column using hexane, hex:AcOEt (95:5) resulting in purification of compound **1** (10 mg) and mixture (368 mg) of two compounds that were purified on MPLC system using silica gel (230-400 mesh), eluting with hex:EtOAc (9:1) and hex:EtOAc (8:2) to give **2** (4.0 mg)

and **3** (13.0 mg). TSM-14 fraction fractionated over silica gel column (70-230 mesh) eluted with hexane, hex:CH₂Cl₂ (20-50%), CH₂Cl₂ and CH₂Cl₂:MeOH (10-50 %), resulted in twenty-one fractions of which frs. 16-19 (2.35 g) were submitted to further silica gel columns chromatography followed by Sephadex LH-20 to give compounds **4** (9.0 mg) and **5** (14 mg).

Microorganisms reference strain and antifungal susceptibility testing

Strains of *Cryptococcus neoformans* (VN1 PCN6) and *Candida albicans* (ATCC 36232) of the culture collection from Instituto Nacional de Pesquisas da Amazônia-INPA, Manaus-AM, were used. These cultures were preserved through lyophilization process, later they were reactivated in Sabouraud Agar Dextrose. An inoculum was removed from the culture and suspended in 5.0 ml of sterile saline 0.085% and placed in vortex for 15 seconds. The cell density was adjusted equivalent to a standard solution of 0.5 McFarland. The suspension for testing was obtained by making a 1/100 dilution followed by a 1/20 dilution in RPMI 1640 (Sigma-Aldrich) buffered with 4-Morpholinepropanesulfonic acid to the required concentrations for the assays according to CLSI¹⁵.

Minimum inhibitory concentration (MIC) assays were performed with the broth microdilution method¹⁵. Briefly, 100 μ L of each evaluated compound diluted in RPMI 1640 broth was added to 96-well microplates, with the initial concentrations of 320 μ g/mL. Amphotericin B was used as the antifungal standard. Next, 100 μ L of an inoculum containing 2.5×10^3 cells/mL of the reference microorganism was added to 96-well microplates. The microdilution plates were incubated at room temperature (35°C) for 24 h. The amount of growth in the tubes containing the tested compound was visually compared with the amount of growth in the growth-control tubes (no antifungal agent) used in each set of tests.

Plasmodium falciparum cultures and Antiplasmodial tests

To assess the schizonticide activity of the compounds against *P. falciparum* *in vitro* were used trophozoite stages in sorbitol-synchronized with approximately 1–2% parasitemia and 2.5% haematocrit¹⁶. All parasites were maintained in continuous culture on human erythrocytes (blood groups A + or O +) using RPMI medium supplemented with 10% human serum as described by Trager & Jensen¹⁷. Then, erythrocytes were distributed in a 96-well plate. The drug stock solutions were prepared in 1% DMSO and further serially diluted (50–0.78 μ g/mL) in complete culture medium. Blood smears were collected after 48 hours, methanol fixed and Giemsa stained, codified and read blindly. The antiplasmodial effect of the isolated compounds was measured by the inhibition of *P.*

falciparum blood parasite growth relative to the control cultures in complete medium without drugs. The parasitemia was observed by optical microscopy. Negative controls were cultures free of treatment, culture in 1% DMSO and culture with addition of distilled water. The parasitemia in control groups without treatment was considered 100%.

The activity of the drug was expressed as the percentage of parasitemia inhibition compared to controls without drugs. Compounds that inhibited between 80 and 100% growth of the parasites were considered active; partially active when the inhibition was between 50 and 79%, and when the inhibition was lower than 50%, the drug was considered inactive¹⁸. The half-maximal inhibitory (IC₅₀) concentration responses were estimated by linear interpolation, as compared to the drug-free controls. A chloroquine control (as a reference antimalarial drug) was used in each experiment. Diluted at a ratio of 1:3 starting from 2500 ng/mL to 3.42 ng/mL in complete culture medium. All experiments were performed in duplicate or triplicate, and the slides were coded for quantification of parasitemia.

Analytical and spectral data of isolated compounds

Dehydro- α -lapachone (**1**): crystalline, orange-colored solid, mp 139–140°C. HRMS m/z 241.0902 [M+H]⁺. ¹H NMR (400 MHz, TMS, CDCl₃, δ , ppm, J/Hz): 8.10–8.09 (2H, m, H-5 and H-8), 7.72–7.68 (2H, m, H-6 and H-7), 6.66 (1H, d, J = 10.0, H-11), 5.73 (1H, d, J = 10.0, H-12), 1.56 (6H, s, H-14 and H-15). ¹³C NMR (100 MHz, CDCl₃, δ , ppm): 181.9 (C-4), 179.9 (C-1), 152.5 (C-2), 134.0 (C-6), 133.2 (C-7), 131.6 (C-9), 131.5 (C-10), 130.9 (C-12), 126.2 (C-5 and C-8), 117.9 (C-3), 115.5 (C-11), 80.5 (C-13), 28.4 (C-14 and C-15).

Dehydro-iso- α -lapachone (**2**): crystalline, yellow-colored solid, mp 109–110°C. HRMS m/z 241.0848 [M+H]⁺. ¹H NMR (400 MHz, TMS, CDCl₃, δ , ppm, J/Hz): 8.10–8.07 (2H, m, H-5 and H-8), 7.74–7.66 (2H, m, H-6 and H-7), 5.42 (2H, dd, J = 10.9 and 8.6, H-12), 5.13 (1H, s br, H-14), 5.01 (1H, sl, H-14), 3.36 (1H, dd, J = 17.2 and 10.9, H-11), 3.04 (1H, dd, J = 17.2 and 8.6, H-11), 1.81 (3H, s, H-15). ¹³C NMR (100 MHz, CDCl₃, δ , ppm): 182.3 (C-4), 177.7 (C-1), 160.1 (C-2), 141.7 (C-3), 134.2 (C-6), 133.0 (C-7), 131.6 (C-10), 126.4 (C-8), 126.1 (C-5), 124.0 (C-9), 114.0 (C-14), 88.5 (C-12), 32.0 (C-11), 16.9 (C-15).

α -Lapachone (**3**): crystalline, yellow greenish solid, mp 119–120°C. HRMS m/z 243.1029 [M+H]⁺. ¹H NMR (400 MHz, TMS, CDCl₃, δ , ppm, J/Hz): 8.10–8.06 (2H, m, H-5 and H-8), 7.70–7.67 (2H, m, H-6 and H-7), 2.62 (H-11, t, J = 6.6, H-11), 1.82 (2H, t, J = 6.6, H-12), 1.44

(6H, s, H-14 and H-15). ¹³C NMR (100 MHz, CDCl₃, δ , ppm): 184.4 (C-4), 180.0 (C-1), 154.7 (C-2), 133.9 (C-6), 132.9 (C-7), 131.2 (C-9), 132.1 (C-10), 126.3 (C-8), 126.0 (C-5), 120.2 (C-3), 78.2 (C-13), 31.5 (C-12), 26.5 (C-14 and C15), 16.7 (C-11).

Paulownin (**4**): crystalline, colourless solid, mp 78.3–81.0°C. HRMS m/z 371.1116 [M-H₂O H]⁺ and m/z 353.1014 [M+H]⁺. ¹H NMR (500 MHz, TMS, CDCl₃, δ , ppm, J/Hz): 6.95 (1H, d, J = 1.7 Hz, H-2), 6.92 (1H, d, J = 1.6, H-2'), 6.88 (1H, d, J = 8.0, H-6'), 6.87 (1H, dd, J = 8.0 and 1.7, H-6), 6.85 (1H, d, J = 8.0, H-5), 6.80 (1H, d, J = 8.0, H-5'), 5.99 (2H, s, H-10'), 5.96 (2H, s, H-10), 4.83 (1H, s, H-7'), 4.86 (1H, d, J = 5.0, H-7), 4.53 (1H, dd, J = 9.2 and 8.1, H-9ax), 4.06 (1H, d, J = 9.4, H-9'ax), 3.92 (1H, d, J = 9.4, H-9'eq), 3.85 (1H, dd, J = 9.2 and 6.1, H-9eq), 3.07 (1H, ddd, J = 8.0, 6.1 and 5.0, H-8). ¹³C NMR (75 MHz, CDCl₃, δ , ppm): 148.2 (C-4'), 148.0 (C-4), 147.9 (C-3'), 147.3 (C-3), 134.6 (C-1'), 129.1 (C-1), 119.8 (C-5), 120.1 (C-6'), 108.6 (C-6), 108.2 (C-5'), 107.4 (C-2'), 106.9 (C-2), 101.3 (C-10'), 101.1 (C-10), 91.6 (C-8'), 87.5 (C-7'), 85.8 (C-7), 74.8 (C-9'), 71.6 (C-9), 60.4 (C-8). HMBC (300 x 75 MHz, CDCl₃): 6.95 → 147.3, 85.8; 6.92 → 87.5; 6.88 → 148.2, 107.4, 87.5; 6.87 → 148.0, 129.1, 106.9, 85.8; 6.85 → 148.0, 129.1; 6.80 → 147.9, 134.6, 120.1; 5.99 → 148.2; 5.96 → 148.0; 4.86 → 129.1, 91.6, 71.6, 60.4; 4.83 → 134.6, 107.4', 120.1; 4.53 → 85.8, 60.4; 4.06 → 91.6, 85.8, 60.4; 3.92 → 91.6, 85.8, 60.4; 3.85 → 85.8, 60.4; 3.07 → 29.1, 91.6.

Cyclooolivil (**5**): Amorphous, white solid, mp 164–66°C. HRMS m/z 375.1567 [M-H]⁺. ¹H NMR (400 MHz, TMS, MeOD, δ , ppm, J/Hz): 6.75 (1H, d, J = 8.0, H-5'), 6.70 (1H, d, J = 1.9, H-2'), 6.66 (1H, dd, J = 8.0 and 1.9, H-6'), 6.62 (1H, s, H-2), 6.18 (1H, d, J = 0.8, H-5), 4.02 (1H, d, J = 11.7, H-7'), 3.81 (1H, dd, J = 11.1 and 2.6, H-9'a), 3.78 (1H, d, J = 11.1, H-9a), 3.77 (3H, s, OMe-3'), 3.59 (1H, d, J = 11.1, H-9b), 3.58 (1H, dd, J = 11.1 and 4.2, H-9'b), 3.21 (1H, d, 16.7, H-7eq), 2.61 (1H, d, J = 16.7, H-7ax), 2.03 (1H, ddd, J = 11.7; 4.2 and 2.6, H-8'). ¹³C NMR (100 MHz, MeOD, δ , ppm): 147.7 (C-31), 146.1 (C-3), 144.7 (C-4'), 143.9 (C-4'), 137.2 (C-1'), 132.1 (C-1), 125.0 (C-6), 122.2 (C-6'), 115.9 (C-5), 114.6 (C-5'), 112.5 (C-2'), 111.6 (C-2), 73.6 (C-8), 68.0 (C-9), 59.4 (C-9'), 54.9 (OMe-3'), 46.2 (C-8'), 43.5 (C-7'), 38.5 (C-7). HMBC (400 x 100 MHz, MeOD): 6.75 → 137.2, 147.7, 144.7; 6.70 → 147.7, 144.7, 122.2, 43.5; 6.66 → 144.7, 112.5; 6.62 → 146.1, 143.9, 132.1, 38.5; 6.18 → 146.1, 125.0, 43.5; 4.02 → 137.2, 132.1, 122.2, 112.5, 59.4, 46.2; 3.81 → 73.6, 46.2; 3.58 → 73.6, 46.2; 3.21 → 132.1, 125.0, 111.6, 73.6, 68.0, 46.2; 3.78 → 73.6, 46.2, 38.5; 3.77 → 147.7; 3.59 → 73.6, 46.2, 38.5; 2.61 →

132.1, 125.0, 111.6, 73.6, 68.0, 46.2; 2.03 → 137.2, 59.4, 43.5.

III. RESULTS AND DISCUSSION

Phytochemical studies with heartwood sawdusts from *H. serratifolius* using different chromatographic techniques resulted in the isolation of compounds identified as dehydro- α -lapachone (**1**), dehydro-iso- α -lapachone (**2**), α -lapachone (**3**), paulownin (**4**) and cyclooolivil (**5**) (Figure 1). Compounds **1** and **3** were identified on basis of ^1H and ^{13}C NMR spectral data and comparison with literature¹⁹ as pyranonaphthoquinone dehydro- α -lapachone and α -lapachone, respectively. In previous studies with heartwood from *H. serratifolius*, dehydro- α -lapachone was detected by GC/MS as predominant compound²⁰. The ^1H and ^{13}C NMR spectral data allowed identification of **2** as dehydro-iso- α -lapachone whose data were similar to those published by Ribeiro et al²¹. Identification of lignans **4** and **5** was based on experiments ^1H and ^{13}C NMR, and HMBC. ^1H and ^{13}C NMR data are in accordance with those reported in the literature as paulownin^{22,23} and cyclooolivil²⁴, respectively. In this study furanonaphthoquinone **2** and lignans **4** and **5** are being reported for the first time from ipê-amarelo wood.




Fig. 1: Compounds isolated from heartwood sawdusts of *H. serratifolius*

Naphthoquinones and lignans were tested against pathogenic strains of *Cryptococcus neoformans* and

Candida albicans (Table 1). Dehydro-iso- α -lapachone (**2**) showed a moderate effect (40 $\mu\text{g/mL}$) against *C. neoformans* strains. Interest in antifungal activity of synthetic and natural naphthoquinones have intensified in recent years. The importance of the search for natural prototypes for these pathogens is due to the small number of drugs available for treatment, the adverse effects associated with the use of certain compounds and the increasing incidence of antifungal resistance²⁵⁻²⁷.

Table 1. MIC ($\mu\text{g/mL}$) of compounds from *H. serratifolius* against *Cryptococcus neoformans* and *Candida albicans*

Compounds	<i>C. neoformans</i>	<i>C. albicans</i>
	VNIPCN6	ATCC 36232
1	80	> 320
2	40	160
3	160	160
4	80	> 320
5	> 320	> 320
Amphotericin B	0.125	0.25

The compounds were evaluated for their *in vitro* antimalarial activity against *Plasmodium falciparum* W-2 a chloroquine-resistant strain. Table 2 shows that naphthoquinones were considered active, the highest activity was observed for furanonaphthoquinone **2** (IC_{50} 7.53 $\mu\text{g/mL}$). The results suggest that the furan-type heterocyclic ring of **2** is important in bioactivity when compared to the pyran ring of naphthoquinones **1** and **3**. Lapachol derivatives are source of inspiration for structural modifications by synthetic transformations for developing new and more active products antiplasmodial against *P. falciparum*^{9,10}. Lignans containing furofuran (**4**) and dibenzilbutane (**5**) skeleton were inactive suggesting chemical transformation for obtaining of their synthetic analogues more active because this class of compounds also has potential antimalarial.

Table 2. Antiplasmodial activity (IC_{50} $\mu\text{g/mL}$) of compounds 1-5 against *Plasmodium falciparum* (W-2)

Compounds	IC_{50}
1	21.12
2	7.53
3	14.00
4	≥ 50
5	≥ 50

IV. CONCLUSION

Phytochemical and biological research on wood residues from species with potential for sustainable use resulted in the identification of compounds with

antimicrobial and antiplasmodial activity. The obtaining of residues from *H. serratifolius* heartwood from the area of management and studies of the technological properties of wood was an opportunity for the increase of knowledge of its secondary metabolism as well as to find active principles.

ACKNOWLEDGEMENTS

The authors thank the Brazilian Agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) for their financial support.

AUTHOR CONTRIBUTIONS

LESM performed the extraction, isolation and identification of constituents. KSC, PILS and JVBS performed in the microbiological activities. CCN performed the identification and anatomical analysis of wood. BMMM and VFAN performed the antiplasmodial assay, AGF performed the NMR experiments. MPL designed the study and supervised the phytochemical laboratory. All authors have read and approved the final manuscript.

REFERENCES

- [1] Tropics (2019, September 18). In Missouri Botanical Garden. Retrieved from <http://www.tropicos.org/name/3701053>.
- [2] Lorenzi, H. (2002). Árvores brasileiras: manual de identificação e cultivo de plantas arbóreas do Brasil. Ed. São Paulo: Nova Odessa.
- [3] González-Coloma, A.; Reina, M.; Sáenz, C.; Lacret, R.; Ruiz-Mesia, L.; Arán, V. J.; Sanz, J.; Martínez-Díaz, R. A. (2012). Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants. *Parasitol. Res.*, 110: 1381-1392.
- [4] Silva, M. N.; Ferreira, V. F.; Souza, M. C. B. V. Um panorama atual da química e da farmacologia de naftoquinonas, com ênfase na b-lapachona e derivados. (2003). *Quim. Nova*, 26: 407-416.
- [5] Araújo, E. L.; Alencar, J. R. B.; Rolim-Neto, P. J. (2002). Lapachol: segurança e eficácia na terapêutica. *Rev. Bras. Farmacogn.*, 12: 57-59.
- [6] Guiraud, P.; Steiman, R.; Campos-Takaki, G. M.; Seigle-Murandi, F.; Buochberg, M. S. (1994). Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. *Planta Med.*, 60: 373-374.
- [7] Ali, R. M.; Houghton, P. J.; Hoo, T. S. (1998). Antifungal activity of some Bignoniaceae found in Malaysia. *Phytother. Res.*, 12: 331-334.
- [8] Oliveira, C. G. T.; Frederico F. Miranda, F. F.; Ferreira, V. F.; Freitas, C. C.; Rabello, R. F.; Carballido, J. M.; Corrêa, L. C. D. (2001). Synthesis and antimicrobial evaluation of 3-hydrazino-naphthoquinones as analogs of lapachol. *J. Braz. Chem. Soc.*, 12: 339-345.
- [9] Andrade-Neto, V. F.; Goulart, M. O. F.; Silva-Filho, J. F.; Silva, M. J.; Pinto, M. C. F. R.; Pinto, A. V.; Zalis, M. G.; Carvalho, L. H.; Krettli, A. U. (2004). Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against *Plasmodium falciparum* in vitro and *Plasmodium berghei* in vivo. *Bioorg. Med. Chem. Lett.*, 14, 1145-1149.
- [10] Perez-Sacau, E.; Estevez-Braun, A.; Ravelo, A. G.; Yapu, D. G.; Turba, A. G. (2005). Antiplasmodial activity of naphthoquinones related to lapachol and beta-lapachone. *Chem. Biodivers.*, 2: 264-274.
- [11] Silva, A. J. M.; Netto, C. D.; Pacienza-Lima, W.; Torres-Santos, E. C.; Rossi-Bergmann, B.; Maurel, S.; Alexis Valentin, A.; Costa, Paulo, R. R. J. (2009). Antitumoral, antileishmanial and antimalarial activity of pentacyclic 1,4-naphthoquinone derivatives. *J. Braz. Chem. Soc.*, 20: 176-182.
- [12] WHO- Global Health Organization (2019 September 09). In Geneva World Health Organization. Retrieved from <http://www.who.int/gho/malaria/en/>.
- [13] Segurado, A. A.; Di Santi, S. M.; Shiroma, M. (1997). *In vivo* and *in vitro* *Plasmodium falciparum* resistance to chloroquine, amodiaquine and quinine in the Brazilian Amazon. *Rev. Inst. Med. Trop.*, 39:85-90.
- [14] Gama, B. E.; Oliveira, N.; Souza, J. M.; Santos, F.; Carvalho, L. J.; Melo, Y. F.; Rosenthal, P. J.; Ribeiro, C. T. D.; Cruz, M. F. (2010). Brazilian *Plasmodium falciparum* isolates: investigation of candidate polymorphisms for artemisinin resistance before introduction of artemisinin-based combination therapy. *Malar. J.*, 9:1-5.
- [15] CLSI/NCCLS. (2008). In Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved Standard M38-A2, 2nd ed.; CLSI: Wayne, PA, USA.
- [16] Lambros, C.; Vanderberg, J. P. (1979). Synchronization of *Plasmodium falciparum* erythrocytic stages in culture. *J. Parasitol.*, 65: 418-420.
- [17] Trager, W.; Jensen, J. B. (1976). Human malaria parasites in continuous culture. *Science*, 193:673-575.
- [18] Carvalho, L. H.; Brandão, M. G. L.; Santos-Filho, D.; Lopes, J. L. C.; Krettli, A. U.; Braz. (1991). Antimalarial activity of crude extracts from Brazilian plants *in vivo* in *Plasmodium berghei* infected mice and *in vitro* against *Plasmodium falciparum* in culture. *J. Med. Biol. Res.*, 24: 1113-1123.
- [19] Jácome, R. L. R. P.; Raslan, D. S.; Wagner, H.; Oliveira, A.B. (2001). Estudo químico de *Zeyheria montana* M. (bolsa de pastor). *Rev. Bras. Farmacogn.*, 11: 5-12.
- [20] Segoloni, E.; Di Maria, F. (2018). GC-MS characterization of *Handroanthus serratifolius* (Vahl.) Grose (a.k.a. *Tabebuia serratifolia* (Vahl.) Nichols/Lapacho) heartwood main extractives: a comparison of protocols aimed at a practical evaluation of

- lapachol and dehydro- α -lapachone content. Eur. J. Wood Wood Prod., 76:1547-1561.
- [21] Ribeiro, C. M. R.; Souza, P. P.; Ferreira, L. L. D. M.; Pinto, L. A.; Almeida, L. S.; Jesus, J. G. (2008). Ciclização do lapachol induzida por sais de tálio III. Quim. Nova, 31: 759-762.
- [22] Laggoune, S.; Brouard, I.; Leon, F.; Calliste, C. A.; Duroux, J.; Bermejo, J.; Kabouche, Z.; Kabouche, A. (2011). Lignans and an abundant flavone glycoside with free-radical scavenging activity from the roots of the endemic species *Stachys mialhesi* de Noé. Rec. Nat. Prod., 5: 238-241.
- [23] Ragasa, C. Y.; Ng Santos, V. A.; Agoo, E. M. G.; Shen, C. C. (2015). Chemical constituents of *Cycas vespertilio*. Rev. Bras. Farmacogn., 25: 526-528.
- [24] Pinheiro, M. L. B.; Rocha, A. F. I.; Fernandes, M. A. (2004). Lignanas de *Strychnos guianensis* (Aublet) Mart. Quim. Nova, 27: 188-192.
- [25] Kathiravan, M. K.; Salake, A. B.; Chothe, A. S.; Dudhe, P. B.; Watode, R. P.; Mukta, M. S.; Gadhwe, S. (2012). The biology and chemistry of antifungal agents: a review. Bioorg. Med. Chem., 20: 5678-5698.
- [26] Zida, A.; Bamba, S.; Yacouba, A.; Ouedraogo-Traore, R.; Guiguemdé, R. T. (2017). Anti-*Candida albicans* natural products, sources of new antifungal drugs: A review. J. Mycol. Med., 27: 1-19.
- [27] Futuro, D. O.; Ferreira, P. G.; Nicoletti, C. D.; Borba-Santos, L. P.; Fernando, C. S.; Rozental, S.; Ferreira, V. F. An. Acad. Bras. Cienc. (2018). The antifungal activity of naphthoquinones: An Integrative Review. An Acad Bras Cienc. 90: 1187-1214.